47 -4 (36) 2021 — Babadzhanov O.A. — STUDY OF THE EFFICIENCY OF ROSACEA THERAPY DEPENDING ON POLYMORPHISM RS1800795 OF THE IL-6 GENE

STUDY OF THE EFFICIENCY OF ROSACEA THERAPY DEPENDING ON POLYMORPHISM RS1800795 OF THE IL-6 GENE

Babadzhanov O.A. Tashkent Pediatric Medical Institute, Ministry of Health of the Republic of Uzbekistan, Tashkent

Resume

The aim of the study was to study the effectiveness of therapy, depending on its severity and frequency distribution of genotypes of the rs1800795 polymorphism of the IL-6 gene in patients with rosacea. The material of the study was 140 unrelated persons with a diagnosis of rosacea at the age from 27 to 69 years, women – 103, men – 37. Most of the cases are people of active working age. The control group consisted of 145 healthy people without skin pathology, which corresponded in terms of gender and age to the group of examined persons.

The diagnosis was made on the basis of the clinical course of the disease, modern methods of clinical, biochemical, laboratory and instrumental examination of patients. and methods for isolating DNA from peripheral blood lymphocytes used the Ribo-sorb kit (AmpliSens, Russia). Testing of the rs1800795 polymorphism of the IL-6 gene was carried out by a standard polymerase chain reaction using thermal cyclers CG-1-96 “Corbett Research” (Australia) and “Applied Biosystems” 2720 (USA), using a commercial kit LLC SMF Liteh (Moscow), according to the manufacturer’s instructions.

The estimation of the deviation of the distributions of genotypes from the canonical distribution of Hardy-Weinberg was carried out using the computer program “GenePop”, which is available on the Internet. The software package “OpenEpi 2009, v.2.3” was used as a tool for statistical calculations.

According to the results of the study, the authors showed the study of gene polymorphism, in particular the rs1800795 polymorphism of the IL-6 gene, will make it possible to predict in advance the effectiveness of therapy and, and to improve the results of treatment of patients, it is necessary to connect additional funds in the form of systemic or local drugs to correct concomitant pathologies or physiotherapeutic procedures taking into account the testimony.

Key words: study of the effectiveness of rosacea therapy, rs1800795 polymorphism of the il-6 gene.

First page

237

Last page

241

For citation: Babadzhanov O.A. STUDY OF THE EFFICIENCY OF ROSACEA THERAPY DEPENDING ON POLYMORPHISM RS1800795 OF THE IL-6 GENE //New Day in Medicine 4(36)2021 237-241 https://cutt.ly/hTEVcA3

LIST OF REFERENCES:

1. Arifov S.S., Babadzhanov O.A. Rozatsea. Monografiya. Tashkent, 2019:175.
2. Babadzhanov O.A. Klinicheskiye i molekulyarno-geneticheskiye osnovy formirovaniya rozatsea. Avtoref. dis… d.m.n. Tashkent, 2019:59.
3. Semonova N.A., Ryazantseva N.V., Novitskiy V.V., Bychkov V.A., Chechina O.Ye. Rol’ polimorfizma gena IL6 –174C/G v razvitii khronicheskoy HCV-infektsii // Byulleten’ sibirskoy meditsiny. – 2010. – № 5. – s. 93-97.
4. Kozak N.A., Pochernyayev A.K., Lytkin D.V., i dr. Odnonukleotidnyy polimorfizm gena interleykina-6 (IL-6) u zhiteley Khar’kova, bol’nykh sakharnym diabetom 2 tipa // Faktori yeksperimental’noi yevolyutsii organizmiv. – 2015. – T.16. – s. 206-209.
5. Shvarts V. Regulyatsiya metablicheskikh protsessov interleykinom 6 // Tsitokiny i vospaleniye. – 2009. – T.8, №3. – s.3-10.
6. Yarmolik Ye.S., Goretskaya M.V., Khvorik D.F. Rol’ angiogeneza i vospaleniya v patogeneze rozatsea // Meditsinskiy zhurnal  (Minsk). – 2016. – №1(55). – s.145-148.
7. Duncan M.R., Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6 // J Invest Dermatol. 1991 Oct;97(4):686-92.
8. Grossman R.M., Krueger J., Yourish D., et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes // Proc Natl Acad Sci U S A. 1989 Aug;86(16):6367-71.
9. Hamzic N., Tang Y., Eskilsson A., et al. Interleukin-6 primarily produced by non-hematopoietic cells mediates the lipopolysaccharide-induced febrile response // Brain Behav Immun. 2013 Oct;33:123-30. doi: 10.1016/j.bbi.2013.06.006.
10. Hunter C.A., Jones S.A. IL-6 as a keystone cytokine in health and disease // Nat Immunol. 2015 May;16(5):448-57. doi: 10.1038/ni.3153.
11. Mellor-Pita S., Citores M.J.,  Castejon R., et al. Monocytes and T lymphocytes contribute to a predominance of interleukin 6 and interleukin 10 in systemic lupus erythematosus // Cytometry B Clin Cytom. 2009 Jul;76(4):261-70. doi: 10.1002/cyto.b.20468.
12. Monfrecola G., Gaudiello F., Cirillo T., et al. Nicotinamide downregulates gene expression of interleukin-6, interleukin-10, monocyte chemoattractant protein-1, and tumour necrosis factor-α gene expression in HaCaT keratinocytesafter ultraviolet B irradiation // Clin Exp Dermatol. 2013 Mar;38(2):185-8. doi: 10.1111/ced.12018.
13. Stannard J.N., Reed T.J., Myers E., et al. Lupus Skin Is Primed for IL-6 Inflammatory Responses through a Keratinocyte-Mediated Autocrine Type I Interferon Loop // J Invest Dermatol. 2017 Jan;137(1):115-122. doi: 10.1016/j.jid.2016.09.008.
14. Tanaka T., Kishimoto T. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases // Int J Biol Sci. 2012;8(9):1227-36. doi: 10.7150/ijbs.4666.
15. Tanaka T., Narazaki M., Kishimoto T. IL-6 in inflammation, immunity, and disease // Cold Spring Harb Perspect Biol. 2014 Sep 4;6(10):a016295. doi: 10.1101/cshperspect.a016295.
16. Villiger P.M., Cronin M.T., Amenomori T., et al. IL-6 production by human T lymphocytes. Expression in HTLV-1-infected but not in normal T cells // J Immunol. 1991 Jan 15;146(2):550-9.
17. Yamaguchi T., Naruishi K., Arai H., et al. IL-6/sIL-6R enhances cathepsin B and L production via caveolin-1-mediated JNK-AP-1 pathway in human gingival fibroblasts // J Cell Physiol. 2008 Nov;217(2):423-32. doi: 10.1002/jcp.21517.